| 查看: 295 | 回复: 2 | |||
madai26银虫 (小有名气)
|
[交流]
【求助】有没有虫子帮我查一下fasidotril这个药在国外有没有上市? 已有2人参与
|
|
因为我们单位没啥数据库,所以查不到。 fasidotril 法西多曲 ACE/NEP双向抑制剂 临床试验做到3期,但后来就没下文了,哪位好心的虫子帮个忙呢?帮我把它有没有上市,在哪上市的查一下? |
» 猜你喜欢
大肠杆菌临床分离菌株ETEC菌株求购
已经有5人回复
钯碳氢气还原脱cbz产物伯胺出现甲基化。
已经有4人回复
药理学论文润色/翻译怎么收费?
已经有271人回复
求助《化工原理》第四版 柴诚敬、贾绍义 课件
已经有1人回复
酯类化合物柱层析极性较大,使用醇类溶剂,怎么避免酯交换
已经有3人回复
求助骆广生微化工技术书籍
已经有1人回复
求助冯连芳、张才亮的《聚合过程强化技术》
已经有1人回复
2026考博
已经有0人回复
浙江中医药大学张勇民院士2026年博士研究生招生
已经有3人回复
硫醚氧化
已经有2人回复
26博士申请-药物化学方向
已经有26人回复
nkbeholder
木虫 (正式写手)
- DRDEPI: 1
- 应助: 11 (小学生)
- 金币: 2945.1
- 散金: 4
- 红花: 5
- 帖子: 748
- 在线: 303.7小时
- 虫号: 202353
- 注册: 2006-03-01
- 性别: GG
- 专业: 药物化学
★ ★
madai26(金币+2):谢谢参与
warlen(金币+1):谢谢参与 2010-08-04 15:15:09
madai26(金币+2):谢谢参与
warlen(金币+1):谢谢参与 2010-08-04 15:15:09
|
这上面写到2期就中止了。 Originator Company: Bioprojet (France) Parent Company: Bioprojet Licensee: Eli Lilly Highest Phase: Discontinued II Development Status: Discontinued II, France, Congestive heart failure Discontinued II, France, Hypertension Discontinued Preclinical, France, Postmyocardial infarction Introduction: Fasidotril, the prodrug of its active metabolite fasidoprilat, is a mixed inhibitor of ACE and neutral endopeptidase. It was undergoing phase II development with Bioprojet in France for the treatment of congestive heart failure and hypertension. It was also in preclinical development for postmyocardial infarction. However, development appears to have been discontinued. In October 2001, Bioprojet and Eli Lilly announced a development and commercialisation collaboration. Under the terms of the agreement, Lilly received exclusive worldwide commercialisation rights excluding Japan and certain countries in Europe. Lilly was to continue to develop fasidotril through to registration, and was to manufacture the finished product; Bioprojet was to manufacture the bulk material. |
2楼2010-08-04 14:45:13
mrzouhao
木虫之王 (文坛精英)
- DRDEPI: 1
- 应助: 179 (高中生)
- 贵宾: 0.108
- 金币: 99716.2
- 散金: 11601
- 红花: 134
- 沙发: 22
- 帖子: 46503
- 在线: 4376.1小时
- 虫号: 201350
- 注册: 2006-02-28
- 专业: 药剂学
3楼2010-08-04 15:13:10











回复此楼